Clinical Trial Update: Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA

View source ↗

Summary

Takeda is providing expanded access to vedolizumab for children and teenagers with Crohn's disease or ulcerative colitis in the United States.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Crohn's Disease, Ulcerative Colitis | Status: AVAILABLE